GAMAMABS PHARMA has a total of 36 patent applications. Its first patent ever was published in 2012. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are PREC BIOLOGICS INC, CHO PHARMA INC and SURFACE ONCOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Canada | 4 | |
#4 | China | 4 | |
#5 | United States | 4 | |
#6 | Brazil | 3 | |
#7 | Republic of Korea | 3 | |
#8 | France | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Dubreuil Olivier | 27 |
#2 | Barret Jean-Marc | 26 |
#3 | Lahmar Mehdi | 19 |
#4 | Prost Jean-François | 17 |
#5 | Degove Stephane | 12 |
#6 | Degove Stéphane | 12 |
#7 | Prost Jean-Francois | 8 |
#8 | Larbouret Christel | 7 |
#9 | Nicolas Andre | 6 |
#10 | Bougherara Houcine | 6 |
Publication | Filing date | Title |
---|---|---|
EP3812008A1 | Amh-competitive antagonist antibody | |
EP3789401A1 | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers | |
KR20200031571A | Inhibitors of cancer-related immunosuppression | |
CN110944665A | AMHRII-binding compounds for preventing or treating lung cancer | |
CA3058282A1 | Amhrii-binding compounds for preventing or treating cancers | |
US2017035903A1 | Antibodies, antibody drug conjugates and methods of use | |
EP3091033A1 | Anti-human-her3 antibodies and uses thereof | |
FR3020063A1 | ANTI-HER4 HUMAN ANTIBODY | |
EP2707391A1 | Antibodies against her3 |